Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Scopia Capital and Neuroderm Ltd (NDRM)

Page 1 of 13

Matt Sirovich and Jeremy Mindich’s Scopia Capital has reported its passive stake in Neuroderm Ltd (NASDAQ:NDRM) via a 13G filing with the Securities and Exchange Commission. According to the filing, Scopia Capital holds around 14.57% of the company’s outstanding common stock, the position containing 3.14 million shares. Scopia Capital initiated a position in Neuroderm during the third quarter of 2015, reporting 1.34 million shares in its last 13F filing.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Scopia Capital Management LP I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 30-0711986 0 3,136,999 0 3,136,999 3,136,999 14.57%
Scopia Windmill Fund LP I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 27-5099941 0 1,876,411 0 1,876,411 1,876,411 8.71%
Scopia Health Care International Master Fund LP I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 98-1234375 0 1,092,198 0 1,092,198 1,092,198 5.07%
Matthew Sirovich I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 0 3,136,999 0 3,136,999 3,136,999 14.57%
Jeremy Mindich I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 0 3,136,999 0 3,136,999 3,136,999 14.57%
Matt Sirovich And Jeremy Mindich
Matt Sirovich And Jeremy Mindich
Scopia Capital

Page 1 of 13 SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No.)*

NeuroDerm Ltd.
(Name of Issuer)
Ordinary Shares, par value NIS 0.01 per share
(Title of Class of Securities)
M74231107
(CUSIP Number)
January 15, 2016
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:

[_]      Rule
13d-1(b)

[X]      Rule
13d-1(c)

[_]      Rule
13d-1(d)

_________

(1) The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The
information required in the remainder of this cover page shall not be deemed to be “filed’ for the purpose of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Page 1 of 13
Loading...